Literature DB >> 8330905

Response of man to endotoxin.

G D Martich1, A J Boujoukos, A F Suffredini.   

Abstract

Endotoxin, a cell wall component of Gram-negative bacteria, plays a central role in the pathogenesis of septic shock. By administering small doses of intravenous endotoxin to humans, a variety of acute inflammatory responses are induced which are qualitatively similar to those that occur during the early stages of septic shock. Within hours of the administration of intravenous endotoxin to human volunteers, changes occur in systemic hemodynamics, ventricular function, pulmonary gas exchange and permeability. In conjunction with these changes in organ function, a wide variety of inflammatory mediators are released which appear to contribute to these responses. These include the release of proinflammatory cytokines (e.g. tumor necrosis factor-alpha, IL-1 beta, IL-6, IL-8), activation of the fibrinolytic system, kallikrein-kinin generation and phospholipase A2 release. Phagocytic leukocytes are primed for enhanced inflammatory responses following endotoxin administration. Counter-regulatory responses are initiated in parallel and may serve to limit some of the end-organ responses by the inflammatory mediators. This human model provides a unique opportunity to extend previous concepts of acute inflammation and to evaluate the earliest responses activated after exposure to an important bacterial component. Defining the pathways and responses initiated during acute human endotoxemia may allow a better understanding of host responses that are critical to the development of organ dysfunction and shock due to severe infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330905     DOI: 10.1016/S0171-2985(11)80353-0

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  59 in total

1.  Response of in vivo protein synthesis in T lymphocytes and leucocytes to an endotoxin challenge in healthy volunteers.

Authors:  A Januszkiewicz; K Loré; P Essén; B Andersson; M A McNurlan; P J Garlick; O Ringdén; J Andersson; J Wernerman
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

2.  Low-level diode laser therapy reduces lipopolysaccharide (LPS)-induced bone cell inflammation.

Authors:  Tsui Hsien Huang; Yu Chuan Lu; Chia Tze Kao
Journal:  Lasers Med Sci       Date:  2011-10-16       Impact factor: 3.161

3.  Safety of endotoxin challenge in healthy volunteers: bradycardia.

Authors:  Bernd Jilma
Journal:  Intensive Care Med       Date:  2005-02-12       Impact factor: 17.440

4.  Limited dynamic range of immune response gene expression observed in healthy blood donors using RT-PCR.

Authors:  Kevin McLoughlin; Ken Turteltaub; Danute Bankaitis-Davis; Richard Gerren; Lisa Siconolfi; Kathleen Storm; John Cheronis; David Trollinger; Dennis Macejak; Victor Tryon; Michael Bevilacqua
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

5.  Molecular dynamics simulations of six different fully hydrated monomeric conformers of Escherichia coli re-lipopolysaccharide in the presence and absence of Ca2+.

Authors:  S Obst; M Kastowsky; H Bradaczek
Journal:  Biophys J       Date:  1997-03       Impact factor: 4.033

6.  Inflammation and Disease: Modelling and Modulation of the Inflammatory Response to Alleviate Critical Illness.

Authors:  Judy D Day; Chase Cockrell; Rami Namas; Ruben Zamora; Gary An; Yoram Vodovotz
Journal:  Curr Opin Syst Biol       Date:  2018-08-23

7.  STAT4 and STAT6 regulate systemic inflammation and protect against lethal endotoxemia.

Authors:  A B Lentsch; A Kato; B Davis; W Wang; C Chao; M J Edwards
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

8.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans.

Authors:  T van der Poll; C C Braxton; S M Coyle; M A Boermeester; J C Wang; P M Jansen; W J Montegut; S E Calvano; C E Hack; S F Lowry
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion.

Authors:  L Shapira; W A Soskolne; Y Houri; V Barak; A Halabi; A Stabholz
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.